Financial Statements and

(d)

Exhibits.

Exhibit No.

Description

5.1

Opinion of Cooley LLP

.

23.1

Consent of Cooley LLP (included in Exhibit 5.1).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRACON Pharmaceuticals, Inc.

Dated: January 13, 2020

By:

/s/ Charles P. Theuer, M.D., Ph.D.

Charles P. Theuer, M.D., Ph.D.

President and Chief Executive Officer

makes a similar move, sign up!

Other recent filings from the company include the following:

Theodore Wang just provided an update on activist position in Tracon Pharmaceuticals, Inc. - Feb. 14, 2020
Ari Zweiman just provided an update on share ownership of Tracon Pharmaceuticals, Inc. - Feb. 13, 2020
Current report, items 7.01 and 9.01 - Feb. 10, 2020
Tracon Pharmaceuticals Announces Change To Nasdaq Capital Market - Feb. 7, 2020
Tracon Pharmaceuticals, Inc.'s Chief Business Officer was just granted 22,000 options - Feb. 4, 2020

Auto Refresh

Feedback